Two grief experts expose the hidden health, social, and economic toll of bereavement—and the policy gaps leaving millions of grieving Americans unsupported.
|Articles|February 1, 2006
Psychiatric Issues in Emergency Care Settings
- Psychiatric Issues in Emergency Care Settings Vol 5 No 1
- Volume 5
- Issue 1
Evaluating for Alcohol and Substance AbuseAlcohol and Drug Abuse Intervention in the Emergency Department: A Step Toward RecoverySubstance Use Disorders in the Emergency SettingDual Diagnosis: A Challenge for ED Clinicians
Advertisement
Editorial
LESLIE S. ZUN, MD, MBA
Patient Assessment
MARCELLO A. MAVIGLIA, MD, MPH
Clinical Case Presentations
MARCELLO A. MAVIGLIA, MD, MPH
Commentary
PETER F. BUCKLEY, MD
also inside: Literature Highlights, Reader Forum, Meeting Calendar
Articles in this issue
over 20 years ago
Back Issues Availableover 20 years ago
Psychiatric Price of Steroid Abuseover 20 years ago
ADD THE BLACK BOX TO MORE LABELS?over 20 years ago
PSYCHIATRIC SYMPTOMS SIGNAL AUTOIMMUNE DISORDERSover 20 years ago
DECADE OF DISCOVERY IN PEDIATRIC BDover 20 years ago
Evaluating for Alcohol and Substance Abuseover 20 years ago
Dual Diagnosis: A Challenge for ED Cliniciansover 20 years ago
Substance Use Disorders in the Emergency SettingAdvertisement
Related to this article
Learn how the inhibition constant and 5-HT2A binding explain LSD effects—and why potent atypical antipsychotics may rapidly end a bad trip.
FDA hearing spotlights debates over psychedelic therapy: who administers, how to prove efficacy, and how to track safety as approvals near.
New US adult ADHD guidance nears publication, promising clearer diagnosis, comorbidity screening, and clinician training to curb misdiagnosis.
New research maps an mPFC–zona incerta circuit that drives punishment-resistant binge eating and hints at personalized brain stimulation targets for better treatment.
Phase 3 BLOOM tests 48-hour at-home oral brexanolone for rapid postpartum depression relief, with tighter monitoring after prior trial issues.
FDA clears Simtriyo, first NDSRI stimulant for ADHD ages 6 and older, as millions return to school—see what this means for treatment.
Phase 2 MOONLIGHT-1 shows JNJ-5120/PIPE-307 misses day‑5 MADRS improvement in MDD, yet remains well tolerated as J&J reviews next steps.
Advertisement
Advertisement
Trending on Psychiatric Times
1
Vol 43, Issue 9 - Interactive
2
FDA Hearing on Psychedelic Medicine Reveals a Field Divided on the Road to Approval
3
Insights on the New Adult ADHD Guidelines: A Conversation With the President of APSARD
4
New Adult ADHD Guidelines: What Resources Are Coming Soon
5